LGR5 and neoplasm: Encouragingly, antibody-mediated blockade of RSPO3 inhibited the growth of PTPRK-RSPO3-fusion-positive human tumour xenografts, compromising the expression of stemness genes (e.g., LGR5, ASCL2, LRIG1, TERT) and promoting differentiation [348].